Related by context. All words. (Click for frequent words.) 72 Thrombolysis 64 composite endpoint 62 SYNTAX 62 thromboembolic events 62 MACCE 61 XIENCE V PROMUS Stent 61 periprocedural 60 symptomatic VTE 60 coronary stenosis 60 Events MACE 60 multicentre randomized 59 TRITON TIMI 59 secondary endpoint 59 definite stent thrombosis 59 Myocardial Infarction Study 59 ipsilateral stroke 59 Randomized Evaluation 58 tirofiban 58 abciximab 58 cerebrovascular events 58 rFVIIa 58 nonfatal MI 58 RE LY 58 NYHA functional class 58 thromboembolic 58 thromboembolism 58 laboratory abnormalities 58 RE LY ® 58 univariate 57 subanalysis 57 binary restenosis 57 Kaplan Meier analysis 57 secondary efficacy endpoint 57 achieved statistical significance 57 echocardiographic 57 nonrandomized 57 cytogenetic response 57 Intracranial 57 XIENCE V demonstrated 57 aortic regurgitation 57 IIIa inhibitor 57 bivalirudin monotherapy 57 events AEs 57 recurrent VTE 57 YMRS 56 noninferiority 56 fondaparinux 56 mg BID dose 56 reinfarction 56 prespecified secondary 56 Myocardial Infarction 56 interobserver reliability 56 ADAS cog 56 recurrent venous thromboembolism 56 Index CDAI 56 death reinfarction 56 prospective randomized controlled 56 EURIDIS 56 platelet reactivity 56 prospective multicenter 56 ischemic cardiomyopathy 56 stenoses 56 STRIDE PD 56 myocardial infarction stroke 56 Angiographic 56 Alzheimer Disease Assessment 56 substudy 56 hemorrhagic complications 56 Acute Myocardial Infarction 56 CHADS 56 PANSS 56 EVEREST II 56 events MACE 55 Major Adverse Cardiac 55 mcg BID 55 virologic response 55 recurrent DVT 55 mcg QD 55 VADT 55 DLTs 55 TAXUS ATLAS 55 secondary efficacy endpoints 55 placebo controlled clinical 55 MEND CABG 55 prespecified 55 QTc prolongation 55 arterial thromboembolic events 55 NIH CPSI 55 eptifibatide 55 Brief Psychiatric 55 QTc 55 carotid stenosis 55 intra arterial 55 sirolimus eluting stents 55 GOUT 55 clinically meaningful improvement 55 virologic failure 55 tolvaptan 55 bypass graft CABG surgery 55 prospective multicenter randomized 55 diameter stenosis 55 TAXUS Express Stent 55 proteinuria 55 febrile neutropenia 55 ATACAND 55 subgroup analyzes 55 extrapyramidal symptoms 55 morphometric vertebral fractures 55 ANOVA 55 LVEF 55 FOLPI 55 left ventricular dysfunction 55 ECG abnormalities 55 carotid endarterectomy CEA 54 histologic 54 eplerenone 54 hematologic toxicity 54 TEAEs 54 Primary endpoints 54 TMC# C# 54 thromboembolic complications 54 ischemia driven 54 NIHSS 54 preoperative PSA 54 preoperatively 54 mg/m2 dose 54 ACCOMPLISH 54 sirolimus eluting stent 54 myocardial ischemia 54 Unified Parkinson Disease 54 PANSS total 54 HDRS 54 Percutaneous Coronary Intervention 54 postoperative complication 54 CIMZIA ™ 54 ECASS 54 ST elevation myocardial 54 Acute Coronary Syndrome 54 Rating Scale MADRS 54 angiographic follow 54 Multicenter 54 GP IIb IIIa inhibitor 54 Coronary Artery Bypass Graft 54 carotid artery stenosis 54 Rating Scale BPRS 54 Negative Syndrome 54 ExTRACT TIMI 54 pericardial effusion 54 Taxus Stent 54 TRANSFORMS 54 multicenter randomized controlled 54 prospectively defined 54 tumor lysis syndrome 54 ventricular fibrillation VF 54 ASTEROID 54 STEMI patients 54 recanalization 54 randomized multicenter 54 doxorubicin docetaxel 54 mg QD 54 DAPT 54 UPDRS 54 liver histology 54 Carotid Revascularization Endarterectomy vs. 54 systemic embolism 54 HOMA IR 54 NATRECOR ® 54 non valvular atrial 54 Montgomery Åsberg Depression 54 atherothrombotic disease 54 vasospasm 54 plus glycoprotein IIb 54 RTOG 54 SYNTAX trial 54 ticagrelor 54 MADIT 54 neoadjuvant 54 lopinavir r arm 53 Scale EDSS 53 Secondary endpoints 53 Stent thrombosis 53 primary endpoint 53 intraobserver 53 perioperative mortality 53 Montgomery Asberg Depression 53 ALLHAT 53 parenchymal 53 virological response 53 artery occlusion 53 hypoglycemic events 53 Psoriasis Area 53 vertebral fracture 53 undetectable HBV DNA 53 bivalirudin 53 thrombolytic therapy 53 treatment emergent adverse 53 Acute Ischemic Stroke 53 PCa 53 MADRS score 53 active comparator 53 STEMI 53 MADRS 53 ALVESCO 53 myocardial infarctions 53 APACHE II 53 periprocedural MI 53 Patency 53 SPIRIT FIRST 53 multicentre 53 everolimus eluting stents 53 Randomised 53 glycoprotein IIb IIIa inhibitors 53 unfractionated heparin UFH 53 biochemical recurrence 53 CNS LS 53 dyssynchrony 53 acute coronary syndromes ACS 53 macrovascular 53 gastroduodenal 53 NYHA class 53 Scale PANSS 53 thrombus aspiration 53 graft occlusion 53 NLX P# 53 ETDRS 53 enoxaparin 53 creatinine clearance 53 Crohn Disease Activity 53 recurrent ischemia 53 coronary revascularization 53 ‰ ¥ 53 reintervention 53 tenecteplase 53 angiographic 53 ARCOXIA 53 mitral regurgitation 53 mg BID 53 ug dose 53 multicenter randomized 53 TAXUS Stent 53 esophageal varices 53 valsartan 53 elevated ALT 53 thrombotic complications 53 ertapenem 53 DAS# [002] 53 subclinical atherosclerosis 53 Subgroup analysis 53 primary efficacy endpoint 53 viral kinetic 53 trials RCTs 53 Secondary endpoints included 53 HAMD 53 Randomized controlled 53 ACR# response 53 ximelagatran 53 ADHD RS 53 PAOD 53 Severity MSCS score 53 Expanded Disability Status 53 hepatotoxicity 53 severe neutropenia 53 PREZISTA r arm 53 P = .# 53 thrombotic events 53 alteplase 53 atheroma volume 53 HGPIN 53 FDA defined valvulopathy 53 noninferior 53 BENICAR HCT 53 anterior uveitis 53 graft dysfunction 53 proximal DVT 53 nonsignificant 53 PEG IFN 53 SVR# 53 ENDEAVOR II 52 rosuvastatin #mg 52 percutaneous intervention 52 Fontan procedure 52 NMIBC 52 oxycodone CR 52 POAG 52 evaluable subjects 52 LV ejection fraction 52 cangrelor 52 infarct size 52 rt PA 52 nonfatal myocardial infarction 52 KOOS 52 β blockers 52 acute coronary syndrome 52 pharmacokinetics PK 52 macrovascular events 52 ROCKET AF 52 4mg/kg 52 variceal bleeding 52 ACUITY trial 52 PRE SURGE 52 exploratory endpoints 52 prospective multicentre 52 angiographic outcomes 52 secondary endpoints 52 cilostazol 52 prognostic variables 52 lumbar spine BMD 52 candesartan cilexetil 52 intima media thickness 52 myocardial infarction MI 52 ≥ 52 WOMAC pain 52 LV dysfunction 52 leukopenia 52 TAXUS stent 52 estimated glomerular filtration 52 multivariate Cox 52 probable stent thrombosis 52 glomerular filtration rate 52 post thrombotic syndrome 52 mucosal healing 52 nab paclitaxel 52 perioperative complications 52 discontinuations due 52 nonfatal stroke 52 RENAL 52 ONTARGET 52 transurethral resection 52 prospectively randomized 52 multicenter randomized placebo controlled 52 subtrochanteric 52 angiotensin converting enzyme inhibitors 52 posttreatment 52 adjunctive placebo 52 Peripheral Arterial 52 PRADAXA #mg 52 SIMPADICO 52 histological subtype 52 efficacy endpoint 52 Atherosclerotic 52 BENICAR 52 platelet inhibition 52 occlusive disease 52 HAM D# scores 52 Monitoring ABPM 52 BARI 2D 52 angiotensin converting enzyme inhibitor 52 repeat revascularization 52 R# #mg BID 52 arterial occlusion 52 multicentre randomized double 52 elotuzumab 52 Ranolazine 52 Kruskal Wallis test 52 NSTE ACS 52 #mg BID [003] 52 Intervention Trial 52 clinically meaningful reductions 52 -#.# ± [002] 52 rebleeding 52 PREVENT IV 52 HbA 1c 52 Hypotension 52 Pain Rating Scale 52 TNSS 52 NTx 52 revascularization 52 ARIXTRA 52 IRLS 52 multicenter randomized clinical 52 bosentan 52 nonparametric 52 carotid intima media 52 irbesartan 52 CYPHER Stent 52 Target Lesion Revascularization TLR 52 graft patency 52 TAXUS IV 52 abdominal pain abdominal discomfort 52 multicenter 52 gout flares 52 prospective randomized 52 multicenter prospective 52 multivariate logistic regression 52 statistical significance 52 certolizumab 52 electrocardiographic 52 elective PCI 52 biopsy Gleason 52 remission CR 52 REYATAZ r arm 52 variceal 52 HAQ DI 52 ventricular tachyarrhythmia 52 Rating Scale UPDRS 52 target vessel revascularization 52 varices 52 primary percutaneous coronary 52 Score TOS 51 UKPDS 51 tapentadol ER 51 allele frequencies 51 superficial femoral 51 limiting toxicity 51 ADAS Cog 51 NSABP B 51 peritumoral 51 hematologic adverse 51 AIM HIGH 51 pharmacokinetic PK 51 angiographically 51 valvulopathy 51 p ≤ 51 renal dysfunction 51 CIMZIA TM 51 lymphadenectomy 51 CIMZIA TM certolizumab pegol 51 Randomized 51 ACR# [002] 51 EDEMA3 51 subscores 51 intraclass correlation coefficient 51 Ambulatory Blood Pressure 51 Edge STudy 51 clinical endpoints 51 RECIST Response Evaluation Criteria 51 UPDRS motor 51 acute coronary syndromes 51 pT3 51 PRECISE 51 univariate analysis 51 Visual Analogue Scale VAS 51 interobserver 51 FOLFIRI 51 hepatectomy 51 chlorambucil 51 cardiovascular hospitalizations 51 carotid IMT 51 cirrhotic patients 51 hyperintense lesions 51 subscore 51 extracranial 51 patients undergoing percutaneous 51 haematologic 51 revascularizations 51 prolonged QT interval 51 malperfusion 51 placebo controlled randomized 51 Scale cognitive subscale 51 Free Survival PFS 51 liver transplant recipients 51 Kaplan Meier curves 51 statistically significant reduction 51 Pain Intensity 51 clinically relevant 51 carotid artery stenting CAS 51 mRS 51 GAMMAGARD 51 PRECiSE 51 RLAI 51 Restenosis 51 Nesiritide 51 nonvertebral fractures 51 postop 51 Non inferiority 51 microalbuminuria 51 aspartate aminotransferase AST 51 Thrombocytopenia 51 posaconazole 51 MR angiography 51 TMC# r 51 PCWP 51 liver resection 51 stable angina 51 Doppler sonography 51 Cardiopulmonary bypass 51 nonresponders 51 apo B 51 NYHA Class II 51 label multicenter 51 dyspnea 51 dose atorvastatin 51 intracranial bleeding 51 nadolol 51 acute myocardial infarction AMI 51 evaluable 51 Endothelial dysfunction 51 mg kg dose 51 adalimumab 51 PFO migraine 51 unstable angina UA 51 macroalbuminuria 51 renal artery stenosis 51 mg TID 51 LEXIVA r 51 IPSS 51 Oral Fingolimod 51 peripheral sensory neuropathy 51 acute myocardial infarction 51 CARE HF 51 plus methotrexate 51 Postoperative 51 CC genotype 51 essential thrombocythemia 51 somatostatin analog 51 gastrointestinal perforation 51 candesartan 51 pulmonary arterial 51 HBeAg seroconversion 51 ischemic stroke 51 Solid Tumors 51 covariate 51 ACTEMRA TM 51 multivariable logistic regression 51 mediastinal 51 stage IIIB 51 CCyR 51 fatal myocardial infarction 51 MEND CABG II 51 TAVR 51 edoxaban 51 methacholine challenge 51 hs CRP 51 syndromal 51 mycophenolate mofetil 51 sirolimus stent 51 ENDEAVOR IV 51 microvascular complications 51 artery stenosis 51 SGRQ 51 hemoptysis 51 FOLFOX4 51 nodular partial response 51 Polyp Prevention Trial 51 non inferiority 51 sustained virologic response 51 TAXUS Liberte Long 51 sUA 51 Pred Forte 51 coronary calcium 51 HBeAg negative patients 51 ULORIC 51 intracerebral hemorrhage 51 radial artery grafts 51 systolic hypertension 51 ALT flares 51 orthostatic hypotension 51 chemoradiotherapy 51 adenoma recurrence 51 intraventricular 51 IV NSCLC 51 Ventricular Tachycardia 51 QTcF 51 transthoracic 51 SerDes transceivers 51 Mean Symptom Complex 51 fluvastatin 51 dosage regimens 51 IABP 51 statistically nonsignificant 51 hypoperfusion 51 Sustained virologic response 51 HCV SPRINT 51 myocardial reperfusion 51 NEVO 51 FDG PET imaging 51 symptomatic intracranial 51 relapsing multiple sclerosis 51 macrovascular disease 51 triglycerides TG 50 cerebral vasospasm 50 International Prostate Symptom 50 DAS# remission 50 multicenter placebo controlled 50 cardiovascular mortality 50 methotrexate monotherapy 50 events SAEs 50 severe exacerbations 50 clinically meaningful improvements 50 QD dosing 50 pneumonectomy 50 hsCRP 50 aminotransferases 50 CYPHER ® Stent 50 tocilizumab 50 Carotid 50 ADCS CGIC 50 nonoperative treatment 50 neointimal hyperplasia 50 stent implantation 50 serum creatinine 50 percutaneous coronary interventions 50 antihypertensive agents 50 intravascular hemolysis 50 Natalizumab 50 nephrotoxicity 50 sustained virological response 50 repeat paracentesis 50 UA NSTEMI 50 prostate cancer CaP 50 WOMAC 50 CRESTOR #mg 50 DAS# CRP 50 randomized multicenter trial 50 cholecystectomy 50 nasal symptom 50 colorectal adenoma 50 Mantel Haenszel 50 rosuvastatin 50 ropivacaine 50 Left Ventricular Ejection Fraction 50 timepoints 50 hypertensive patients 50 neovascular AMD 50 Erythropoietic therapies may 50 discontinuations 50 bivariate 50 Durezol 50 Disease Activity 50 antipsychotic efficacy 50 fosbretabulin 50 cerebrovascular accident 50 mm Stent 50 phase IIIb 50 CTEPH 50 mitral stenosis 50 stent thrombosis 50 bypass grafting 50 patients undergoing CABG 50 ischemic complications 50 NIHSS score 50 nadroparin 50 residual stenosis 50 atherogenic dyslipidemia 50 randomized controlled trials RCTs 50 Bonferroni correction 50 p = #.# [003] 50 unfractionated heparin 50 anemia hemoglobin 50 LOVENOX 50 functional mitral regurgitation 50 Meta analyzes 50 Kaplan Meier survival 50 teriflunomide 50 cardioembolic stroke 50 serum testosterone 50 nicardipine 50 prospective randomized multicenter 50 SPIRIT III 50 ADHF 50 antiplatelet agent 50 fibrinolysis 50 endobronchial 50 PEGylated interferon beta 1a 50 dose limiting toxicities 50 comparator arm 50 % Confidence Interval 50 AST ALT 50 inflammatory lesions 50 NSTEMI 50 Sorafenib HCC Assessment 50 multicenter randomized double 50 keloid scarring 50 clopidogrel 50 infarctions 50 TAXUS Liberte Stent 50 lymphocytosis 50 postoperatively 50 acute ischemic stroke 50 p = #.# [002] 50 logistic regression analysis 50 landmark ATHENA trial 50 sinus tachycardia 50 pheochromocytoma 50 treated nonoperatively 50 Ejection Fraction 50 underwent resection 50 IIb 50 primary aldosteronism 50 beta blocker therapy 50 hemodialysis patients 50 edifoligide 50 interrater reliability 50 DES implantation 50 QRS duration 50 aspartate aminotransferase 50 baseline HbA1c 50 serum phosphorous 50 etiologic 50 carotid revascularization 50 preoperative 50 genotypic resistance 50 Response Evaluation Criteria 50 stent thromboses 50 tiotropium 50 budesonide formoterol 50 postoperative atrial fibrillation 50 Secondary efficacy endpoints 50 NATRECOR R 50 BRIM2 50 T1a 50 mcg albinterferon alfa 2b 50 p = .# [002] 50 IBDQ 50 ACR# ACR# 50 adjunctive ABILIFY 50 T2DM 50 evaluable patients 50 undergoing coronary angiography 50 stenosis 50 nonfatal myocardial infarction MI 50 microvascular disease 50 arteriography 50 reoperations 50 Pharmacokinetic 50 statistically significant p = 50 reperfusion therapy 50 serologically active patients 50 galiximab 50 Lp PLA2 50 valvular disease 50 paclitaxel eluting stents 50 IFN α 50 NNT = 50 HAM D 50 left ventricular LV 50 bronchial hyperresponsiveness 50 Y BOCS 50 cardiac biomarkers 50 hypoxemia 50 multivariable analysis 50 mL min 50 renal impairment 50 HRCT 50 Phase IIIb 50 atherothrombotic 50 docetaxel pretreated 50 leukocyte count 50 target lesion revascularization 50 electrophysiologic 50 primary endpoints 50 treatment emergent AEs 50 endophthalmitis 50 corrected QT interval 50 postoperative AF 50 CR CRu 50 hypomagnesemia 50 vWD 50 EDEMA4 trial 50 NYHA 50 randomized blinded 50 nondiabetic patients 50 HYVET 50 ALT elevations 50 Retisert TM 50 SORT OUT III 50 subclinical hypothyroidism 50 Phase III randomized 50 intraoperative complications 50 subscale scores 50 randomisation 50 Stenosis 50 unstable angina pectoris 50 inotropic therapy 50 intraocular inflammation 50 ruboxistaurin 50 apnea hypopnea index 50 conditional logistic regression 50 CALGB 50 thrombolysis 50 landmark ATHENA 50 TAXUS Element Stent 50 rs# [004] 50 tertile 50 Tiotropium 50 CDAI 50 annualized relapse 50 hepatic cirrhosis 49 Prehypertension 49 cardiac dysfunction 49 Pearson correlation coefficient 49 Acute Decompensated Heart Failure 49 TIMP 1 49 oral allopurinol 49 receiving VICTRELIS 49 AGILECT ® 49 hemodynamic instability 49 hepatic encephalopathy 49 angioplasty stenting 49 biochemical relapse 49 jugular venous 49 MIST II 49 darunavir ritonavir 49 CR nPR 49 FACIT 49 TAXUS Liberté stent 49 mTSS 49 ischemic lesions 49 lymphocyte counts 49 claudication 49 neutropenia dehydration dyspnea 49 HIV RNA 49 LEVADEX 49 intracerebral 49 virologic 49 IRLS score 49 pretest probability 49 retinal vein occlusion 49 ABSORB trial 49 postoperative complications 49 PsA 49 prostate cancer PCa 49 Abciximab 49 recombinant tissue plasminogen 49 mg dose 49 serum triglycerides 49 â ‰ ¥ 49 desvenlafaxine succinate 49 gadolinium enhanced 49 postoperative delirium 49 TORISEL 49 undergoing coronary artery 49 Secondary endpoints include 49 stenotic 49 #mg QD [002] 49 Health Assessment Questionnaire 49 HbA1c levels 49 glomerular filtration 49 hyperkalemia 49 MDRD 49 coronary intervention 49 dapagliflozin plus 49 intracoronary 49 CABG coronary artery 49 #mg/m# [001] 49 AUC0 49 Solid Tumors criteria 49 somatic symptom 49 T1 weighted images 49 IIIa inhibitors 49 mg qd 49 prospective randomized placebo 49 prognostic factors 49 GP IIb IIIa inhibitors 49 ascending dose 49 logistic regression model 49 colesevelam HCl 49 hallux valgus 49 peri procedural 49 segment binary restenosis 49 glycated hemoglobin levels 49 Multicenter Automatic Defibrillator Implantation 49 cerebral infarction 49 hemodynamically significant 49 Afib 49 Solid Tumors RECIST 49 blood Phe 49 mCi kg 49 plasma pharmacokinetics 49 carotid endarterectomy 49 CRp 49 HSCT 49 vitreous hemorrhage 49 left ventricular systolic 49 Octreolin 49 antithrombotic therapy 49 NYHA Class III 49 Critical Limb Ischemia CLI 49 stent restenosis 49 histologically proven 49 apolipoproteins 49 intact parathyroid hormone 49 calculated creatinine clearance 49 bi ventricular pacing 49 inotropic 49 mL sec 49 HAM D# 49 Val HeFT 49 label multicenter Phase 49 sternotomy 49 angina pectoris 49 ritonavir boosted 49 postoperative 49 double blinded placebo 49 histologic subtype 49 QT prolongation 49 MIs 49 mITT 49 β blocker 49 infusional 49 confidence intervals CIs 49 sensory neuropathy 49 Cypher Stent 49 μmol L 49 noncardiac 49 randomized controlled clinical 49 Coronary artery bypass grafting 49 mildly symptomatic 49 CELLO 49 postprocedure 49 urinary N telopeptide 49 GORE VIABAHN Endoprosthesis 49 8mg/kg 49 intermittent claudication 49 ischemic 49 saphenous vein graft 49 alanine aminotransferase 49 arteriolar 49 lipid parameters 49 NEVO ™ 49 splenectomized patients 49 #mg BID [001] 49 heparin induced thrombocytopenia 49 advanced adenoma 49 histologically confirmed 49 oral anticoagulation 49 thrombophlebitis 49 prospectively stratified 49 statistically significant differences 49 postoperative radiographs 49 #mmHg [001] 49 coronary angiography 49 antiplatelet drugs 49 cerebral ischemia 49 occlusions 49 invasive aspergillosis 49 sonographic findings 49 lamivudine refractory patients 49 CrCl 49 pyelonephritis 49 EDSS scores 49 rivaroxaban 49 RVOT 49 GISSI HF 49 controlled multicenter 49 mL/min/#.# m 2 49 Cmax 49 reoperation 49 noncalcified 49 catheter occlusion 49 Neovascular AMD 49 parathyroidectomy 49 HCV RESPOND 2 49 MoxDuo TM IR 49 octreotide LAR 49 haemodynamic 49 cerebrovascular accidents 49 CD4 + cell 49 riociguat 49 ACTEMRA 49 pharmacodynamic effects 49 serum sodium 49 PSADT 49 COPD exacerbation 49 Ashworth Scale 49 urolithiasis 49 systolic dysfunction 49 cells mcL 49 timepoint 49 histopathologic 49 carotid plaque 49 oncologic outcomes 49 obscure gastrointestinal bleeding 49 vasculopathy 49 onset diabetes mellitus 49 alicaforsen enema 49 primary patency 49 multicenter trials 49 CABG 49 CORD II 49 thrombolytic agents 49 p = #.# [004] 49 histologically 49 postoperative mortality 49 choroidal neovascularization 49 bowel resection 49 Score IPSS 49 hydronephrosis 49 revascularization procedures 49 CHAMPION PCI 49 Kaplan Meier estimates 49 atrioventricular block 49 symptom severity 49 Postoperative complications 49 carboplatin paclitaxel 49 CLINICAL PHARMACOLOGY 49 clinicopathologic 49 oral prednisolone 49 intracerebral haemorrhage 49 #OHD 49 regression analyzes 49 MADIT II 49 nausea photophobia 49 saphenous vein grafts 49 cardiac tamponade 49 cardiovascular hospitalization 49 APPRAISE 49 MCyR 49 #.#mg/dL